Lundbeck Q3 2019 Financial Results

9M 2019 and FY 2018 - Geographic distribution of revenue - 2 DKKm FY 2018 FY 2017 9M 2019 9M 2018 Growth Growth in local currencies % of total EUROPE: Abilify Maintena 770 637 715 587 22% 21% 30% Brintellix 547 376 523 396 32% 31% 22% Cipralex 572 643 422 467 (10%) (10%) 17% Rexulti/Rxulti 7 Other pharmaceuticals 1,081 1,149 750 819 (8%) (9%) 31% Total revenue 2,970 2,805 2,417 2,269 7% 6% 100% INTERNATIONAL MARKETS: Abilify Maintena 130 105 124 94 32% 34% 4% Brintellix 396 313 397 294 35% 39% 13% Cipralex/Lexapro 1,552 1,582 1,283 1,324 (3%) (4%) 42% Rexulti 21 2 28 11 162% 160% 1% Other pharmaceuticals 1,401 1,404 1,190 1,083 10% 9% 40% Total revenue 3,500 3,406 3,022 2,806 8% 8% 100% 58 Lundbeck

View entire presentation